BIO India to Spur Cross-Border Collaborations and Partnership Deals

BIO India will be held September 12-13 at the Grand Hyatt Mumbai

BIO India to Spur Cross-Border Collaborations and Partnership Deals

<0> Biotechnology Industry OrganizationSrinivas Ram, +91 9000793986orAbigail Hirsch, 1-202-962-9235 </0>

The Biotechnology Industry Organization (BIO) today announces the initial selection of presenting companies for the 3rd Annual , September 12-13 at the Grand Hyatt in Mumbai, India. Through company presentations and partnering opportunities available at the BIO India event, attendees will be able to connect with other industry leaders to discuss potential collaborations and deals.

BIO brings to India more than ten years experience and expertise in biotechnology and pharmaceutical partnering. BIO is renowned for its successful partnering meetings held around the globe, including the industry’s largest partnering event – the BIO Business Forum at the BIO International Convention.

“BIO India is a unique event that allows biotech and pharmaceutical leaders from around the world to gather and explore potential partnerships and collaborations with India’s life science companies. It is our hope that attendees and presenters alike capitalize on the exceptional opportunities available only at this event,” said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO.

BIO India will once again feature company presentations by biotech and pharmaceutical companies. One-on-One Partnering™ system. To apply to present at BIO India, .

As of today, the following companies are scheduled to present at this year’s event:

India’s biotech and pharmaceutical space is world class, and the number and type of collaborations between Indian and US or EU companies has grown rapidly in the past few years. Event attendees will have the opportunity to connect with industry leaders through BIO’s One-on-One Partneringsystem to 30-minute meetings in private rooms provided by BIO onsite at the conference. This industry-specific, web-based interactive software enables participants to move efficiently from the identification of prospective partners to discussion and negotiations. To learn more about the system, including its evolution, read .

Through this conference and ongoing advocacy efforts, BIO aims to help the industry flourish within India's borders and help patients and citizens benefit from the promise of biotech. BIO has partnered with the Association of Biotechnology Led Enterprises (ABLE), which represents Indian and Asian biotechnology and pharmaceutical companies, as well as leading investment banks and Venture Capital firms.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.”

ABLE – Association of Biotechnology Led Enterprises is a national forum that represents the Indian Biotechnology Sector. The primary objective of ABLE is to accelerate the pace of growth of the Biotechnology Industry in India, through partnering with the Government of India in their Biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaborations and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector. ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors.

September 12 – 13, 2012Mumbai, India

September 19 – 21, 2012Kansas City, MO

October 9-10, 2012San Francisco, CA

October 10 – 12, 2012Vancouver, Canada

October 24 – 25, 2012Shanghai, China

November 12 – 14, 2012Charleston, SC

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.